DAA936 |
Volume of hematopoietic bone marrow decreases |
— |
bone marrow |
Human |
|
DAA939 |
Naive cell number increases and memory cells decrease |
— |
B cell |
Human |
|
DAA940 |
B naive cells' susceptibility to apoptosis decreases |
— |
memory B cell |
Human |
|
DAA944 |
Less antibodies generated |
— |
B cell |
Human |
|
DAA945 |
Thymus involution |
— |
thymus |
Human |
|
DAA946 |
Thymic hormone levels decrease |
— |
plasma |
Human |
|
DAA948 |
Volume of perivascular space around thymus increases |
— |
thymus |
Human |
|
DAA950 |
Immune response to Epstein-Barr virus decreases in cytomegalovirus positive individuals |
— |
immune system |
Human |
|
DAA952 |
Fewer CD4+ and CD8+ cells |
— |
T cell |
Human |
|
DAA953 |
Increase in cells that are both CD8+ and CD28-null |
— |
T regulatory cell |
Human |
|
DAA954 |
Number of T cell progenitors declines |
— |
T cell progenitor |
Human |
|
DAA955 |
Interleukin-7 production declines |
— |
stromal cell |
Human |
|
DAA956 |
Proliferation is reduced |
— |
lymphocytes |
Human |
|
DAA960 |
Receptor expression alterations |
— |
grey matter |
Human |
|
DAA961 |
Increased apoptosis associated with Fas and Fas-ligand expression |
— |
T cell |
Human |
|
DAA962 |
Interleukin-2 production in response to influenza vaccine declines |
— |
T cell |
Human |
|
DAA963 |
Expansion into effector cells is reduced |
— |
naïve T cell |
Human |
|
DAA964 |
T-cell diversity declines |
— |
T cell |
Human |
|
DAA965 |
Incidence of anergia increases |
— |
immune system |
Human |
|
DAA966 |
Vaccination antibody response is impaired |
— |
immune system |
Human |
|
DAA968 |
Chronic inflammation increases |
— |
blood, immune system |
Human |
|
DAA972 |
Chemotaxis and adhesion activity unchanged in vitro |
— |
neutrophil |
Human |
|
DAA973 |
Chemotaxis and respiratory burst capacity in response to GM-CSF priming decreased |
— |
neutrophil |
Human |
|
DAA974 |
Chemotaxis is reduced |
— |
neutrophil, dendritic cell |
Human |
|
DAA975 |
Infiltration at injury site is reduced |
— |
neutrophil |
Human |
|